Solara Active Pharma Sciences - PP , a prominent player in the pharmaceutical industry, has announced significant changes to its board composition, committee structure, and organizational roles. The company disclosed these developments in regulatory filings.

Key Highlights

• Director Resignation: Mr. Kartheek Chintalapati Raju has stepped down from his position as Non-Executive Director, effective November 5, 2025.
• Reason for Departure: The resignation is attributed to preoccupation and personal commitments.
• Committee Changes: Mr. Raju's departure also affects his roles in the Stakeholders Relationship Committee and Nomination and Remuneration Committee.
• Board Restructuring: The company's Board of Directors has reconstituted both committees following the resignation.
• New Appointments and Role Changes: The Board approved several organizational changes, including new appointments and role expansions.
• New CHRO Appointment: Mohanraj S has been appointed as Chief Human Resources Officer and designated as Senior Management Personnel.

Reconstituted Committees

Stakeholders Relationship Committee

Nomination and Remuneration Committee

Organizational Changes

• Chief Investor Relations Officer: Sarat Kumar Asuri, the current Chief Financial Officer, has been appointed to the additional role of Chief Investor Relations Officer.
• Remuneration Revision: The board revised the remuneration of Whole-time Director Mohan Muthunarayanan within previously approved shareholder limits.
• Senior Management Compensation: The company updated compensation for eligible Senior Management Personnel.
• Risk Management: The existing Risk Management Policy was reviewed and confirmed.
• Chief Human Resources Officer: Mohanraj S has been appointed as Chief Human Resources Officer and designated as Senior Management Personnel, effective November 5, 2025.

New CHRO Profile

Mohanraj S brings over 30 years of cross-industry experience to his new role as Chief Human Resources Officer. His expertise spans various sectors including Pharma, Biotech, Engineering, Aerospace, Apparel, and Media. Mohanraj's areas of specialization include:

• Talent Management
• Employee Relations
• Organizational Development
• HRIS
• Digital Transformation

Prior to joining Solara Active Pharma Sciences - PP, Mohanraj held HR leadership positions at notable organizations such as Mylan Laboratories, The Manipal Group, and Tata Advanced Materials. His educational background includes:

• Masters in Social Work (HRM) from Madras University
• BA in Behavioural Sciences from St. Josephs College, Bangalore

Additionally, Mohanraj is a certified ISO auditor and has served on the Board of Studies for Industrial Relations at St. Josephs University for two decades.

The company expressed its appreciation for Mr. Raju's contributions during his tenure, acknowledging the value of his experience and guidance to Solara Active Pharma Sciences - PP.

These changes in the board structure, committee compositions, and organizational roles are expected to ensure continued strong governance and oversight at Solara Active Pharma Sciences - PP. The company remains committed to maintaining high standards of corporate governance and adapting its leadership structure to meet evolving business needs.

Solara Active Pharma Sciences - PP , a leading pharmaceutical company, has released its unaudited financial results for the second quarter and half-year ended September 30, 2025. The results, approved by the Board of Directors on November 5, 2025, reveal a challenging quarter for the company, primarily due to short-term operational disruptions.

Key Financial Highlights

Performance Analysis

Solara Active Pharma faced significant challenges in Q2 FY26, primarily due to an unscheduled operational shutdown at its Mangalore facility for upgradation purposes. This disruption led to delayed deliveries and reduced sales volumes during the quarter.

Revenue and Profitability

• Q2 FY26 revenue stood at INR 314.00 crores, down 9.6% year-on-year and 1.9% quarter-on-quarter.
• The company reported a net loss of INR 10.10 crores in Q2 FY26, compared to a profit of INR 7.90 crores in Q2 FY25.
• EBITDA margin contracted to 11.30% in Q2 FY26 from 17.70% in Q2 FY25, primarily due to the operational disruptions and one-time additional operating costs.

Market Focus

• Regulated markets continued to be a key focus, constituting 75% of total revenues in Q2 FY26.

Balance Sheet Management

• Gross debt as of September 30, 2025, was INR 623.30 crores, reduced by INR 152.70 crores from the end of FY25.
• The company aims to further reduce debt through a combination of rights issue proceeds and operating leverage.

Strategic Initiatives

1. Rights Issue: Solara has raised INR 311.85 crores through a rights issue, with plans to raise an additional INR 134.99 crores in the final call.

2. Business Restructuring: The company is exploring the demerger of its CRAMS (Contract Research and Manufacturing Services) and Polymers business into an independent listed entity, Synthix Global Pharma Solutions Limited.

3. Facility Upgradation: Despite short-term impacts, the company continues to invest in facility upgrades to enhance long-term operational efficiency.

Management Commentary

Sandeep Rao, MD & CEO, stated, "While these factors influenced current quarter results, they are transitory. The underlying fundamentals of the business remain strong, supported by a resilient operating model, robust compliance framework, and a diversified portfolio across key markets."

Outlook

Despite the short-term challenges, Solara Active Pharma maintains a positive long-term outlook. The company expects to leverage its strong presence in regulated markets, focus on high-margin segments, and ongoing cost optimization efforts to drive future growth and profitability.

Investors and stakeholders will be closely watching how Solara navigates these short-term disruptions and executes its strategic initiatives in the coming quarters.

Note: All financial figures are in Indian Rupees (INR) and are on a consolidated basis unless otherwise stated.